Degron Therapeutics Closes $40M Series A Extension Advancing Molecular Glue Degrader

Degron Therapeutics has closed a $40 million Series A extension aimed at advancing its lead molecular glue degrader program, DEG6498. As a clinical-stage biotechnology company, Degron advances molecular glue degrader (MGD) medicines targeting previously undruggable or insufficiently drugged proteins.

Investors Show Interest in Degron

Lapam Capital led the financing round that brought Degron’s total capital raised to $95 million. Additional investors included GTJA Investment Group, Fortune Capital, CSPC & Growth, ApicHope, GF Xinde, Casstar, Kinghall Ventures, and Gage Capital.

The funding will also go toward ongoing expansion of Degron’s proprietary GlueXplorer platform. The design of this platform is to generate potential first-in-class, best-in-disease molecular glue degrader candidates.

“[The investors] share our vision for transforming the treatment of serious diseases,” said Degron Co-Founder and CEO Lily Zou, PhD.

Explaining the Molecular Glue Degrader

DEG6498, a first-in-class human antigen R (HuR) MGD, entered the clinic in late 2025, with the first patient dosed in November. The program targets a previously undruggable RNA-binding protein that has key roles in driving cancer, inflammation, and metabolic disorders. DEG6498 is currently in dose escalation in a Phase I study involving patients with advanced solid tumors.

“The strong interest from leading healthcare investors underscores confidence in our approach to developing novel MGDs,” Zou said. “We are making significant progress toward our goal of delivering breakthrough therapies to improve patients’ lives.”

Lapam Capital Chairman Zhihua Yu also commented, in a press release.

“We are pleased to lead this financing round for Degron,” Yu said. “With this financing, we believe Degron is well-positioned to advance its pipeline efficiently and generate compelling data to benefit patients.”

Beside this funding, Degron says it is partnering with leading pharmaceutical and biotech companies—namely an ongoing collaboration with Takeda.